Clinical Trial Update: A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating AK104 in combination with Chiauranib for extensive-stage small cell lung cancer has completed; no specific results are described in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Chiauranib (Chiauranib)

Snippet

Sponsor: Akeso | Conditions: SCLC,Extensive Stage | Phase 1, Phase 2 | Status: COMPLETED